[{"id":"442d5c06-75a4-48d9-85ea-9b9fc557a2ef","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT03252938","created_at":"2021-01-17T17:46:57.179Z","updated_at":"2025-02-25T15:10:38.137Z","phase":"Phase 1","brief_title":"Feasibility and Safety of IMP321 (eftilagimod Alpha) for Advanced Stage Solid Tumors","source_id_and_acronym":"NCT03252938 - INSIGHT","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 08/15/2017","start_date":" 08/15/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-13"},{"id":"9769a239-dda3-451c-affd-0604dae6b7e4","acronym":"TACTI 002","url":"https://clinicaltrials.gov/study/NCT03625323","created_at":"2021-01-17T17:19:46.423Z","updated_at":"2025-02-25T16:08:11.649Z","phase":"Phase 2","brief_title":"Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC","source_id_and_acronym":"NCT03625323 - TACTI 002","lead_sponsor":"Immutep S.A.S.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Completed","enrollment":" Enrollment 187","initiation":"Initiation: 02/18/2019","start_date":" 02/18/2019","primary_txt":" Primary completion: 06/02/2022","primary_completion_date":" 06/02/2022","study_txt":" Completion: 11/25/2024","study_completion_date":" 11/25/2024","last_update_posted":"2024-12-18"},{"id":"4643a56d-2068-41bc-9998-b846c8a36b96","acronym":"KEYNOTE-C34","url":"https://clinicaltrials.gov/study/NCT04811027","created_at":"2021-03-23T11:52:10.624Z","updated_at":"2025-02-25T16:11:17.415Z","phase":"Phase 2","brief_title":"Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC","source_id_and_acronym":"NCT04811027 - KEYNOTE-C34","lead_sponsor":"Immutep S.A.S.","biomarkers":" CTLA4","pipe":" | ","alterations":" PD-L1 expression","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 08/27/2021","start_date":" 08/27/2021","primary_txt":" Primary completion: 03/11/2024","primary_completion_date":" 03/11/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-10-31"},{"id":"86fab96d-2e9b-46db-bfb5-1b9bf74ce73a","acronym":"AIPAC-003","url":"https://clinicaltrials.gov/study/NCT05747794","created_at":"2023-02-28T13:01:27.736Z","updated_at":"2024-07-02T16:35:04.109Z","phase":"Phase 2/3","brief_title":"Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy","source_id_and_acronym":"NCT05747794 - AIPAC-003","lead_sponsor":"Immutep S.A.S.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HR negative • PGR positive","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HR negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ImmuFact (eftilagimod alpha)"],"overall_status":"Recruiting","enrollment":" Enrollment 849","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-05-13"},{"id":"8fa58053-0b08-4b41-a0ac-b31db9903d83","acronym":"KEYNOTE-PN798","url":"https://clinicaltrials.gov/ct2/show/NCT03625323/","created_at":"2021-01-17T17:19:46.651Z","updated_at":"2024-02-04T01:02:49.141Z","phase":"Phase 2","brief_title":"Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC","source_id_and_acronym":"2018-001994-25 - KEYNOTE-PN798","lead_sponsor":"Immutep S.A.S.","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 189","initiation":"Initiation: 02/18/2019","start_date":" 02/18/2019","primary_txt":" Primary completion: 06/02/2022","primary_completion_date":" 06/02/2022","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-10-24"},{"id":"a1ce51bc-6cd1-421d-986a-f71dedfe9698","acronym":"AIPAC-002","url":"https://clinicaltrials.gov/study/NCT04252768","created_at":"2021-01-18T20:39:58.837Z","updated_at":"2024-07-02T16:35:52.762Z","phase":"Phase 1","brief_title":"A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel","source_id_and_acronym":"NCT04252768 - AIPAC-002","lead_sponsor":"Immutep S.A.S.","biomarkers":" ER • PGR • IFNG","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ImmuFact (eftilagimod alpha)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-03-22"},{"id":"a435e395-9ef6-4a23-93c6-21a5a69cadeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05322720","created_at":"2022-04-12T14:52:53.461Z","updated_at":"2024-07-02T16:36:13.164Z","phase":"Phase 2","brief_title":"HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy","source_id_and_acronym":"NCT05322720","lead_sponsor":"Taizhou EOC Pharma Co., Ltd.","biomarkers":" HER-2 • ER • PGR • IFNG • CXCL10","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • ER • PGR • IFNG • CXCL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • ImmuFact (eftilagimod alpha)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2022-04-12"},{"id":"83546b82-57fc-4995-bda9-6c2ed77ab19e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03600090","created_at":"2021-01-18T17:41:58.905Z","updated_at":"2024-07-02T16:36:14.390Z","phase":"Phase 1","brief_title":"Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT03600090","lead_sponsor":"Taizhou EOC Pharma Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ImmuFact (eftilagimod alpha)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 12/25/2021","primary_completion_date":" 12/25/2021","study_txt":" Completion: 12/25/2021","study_completion_date":" 12/25/2021","last_update_posted":"2022-03-31"},{"id":"ca1b29a3-3fb9-46a1-8c2e-fa08868fa33d","acronym":"AIPAC","url":"https://clinicaltrials.gov/study/NCT02614833","created_at":"2021-01-18T12:42:15.692Z","updated_at":"2024-07-02T16:36:23.445Z","phase":"Phase 2b","brief_title":"IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma","source_id_and_acronym":"NCT02614833 - AIPAC","lead_sponsor":"Immutep S.A.S.","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ImmuFact (eftilagimod alpha)"],"overall_status":"Completed","enrollment":" Enrollment 242","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2021-10-05"}]